Appendix B. Sources of evidence considered by the Committee

A. The evidence review group (ERG) report for this appraisal was prepared by the School of Health and Related Research (ScHARR):

D Hind, P Tappenden, J Peters, K Kenjegalieva. Varenicline for smoking cessation: a single technology appraisal(March 2007).

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope. Organisations listed in I were also invited to make written submissions. Organisations listed in II gave their expert views on varenicline by providing a written statement to the Committee. Organisations listed in I and II have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • Pfizer Ltd

II) Professional/specialist and patient/carer groups:

  • Action Heart

  • British Heart Foundation

  • Burnley, Pendle and Rossendale PCT

  • Cancer Research UK

  • General Practice Airways Group

  • Macmillan Cancer Relief

  • National Lung Cancer Forum for Nurses

  • Primary Care Cardiovascular Society

  • Roy Castle Lung Cancer Foundation

  • Royal College of Nursing

  • Royal College of Physicians

  • Welsh Assembly Government

III) Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • British Society for Cardiovascular Research

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • GlaxoSmithKline (Bupropion)

  • GlaxoSmithKline Consumer Healthcare (Nicotine)

  • Medicines and Healthcare Products Regulatory Agency (MHRA)

  • National Coordinating Centre for Health Technology Assessment

  • NHS Quality Improvement Scotland

  • School of Health and Related Research (ScHARR), University of Sheffield

C. The following individuals were selected from clinical specialist and patient advocate nominations from the professional/specialist and patient/carer groups. They gave their expert personal view on varenicline by providing written evidence to the Committee.

  • Dr Katherine Willmer, Consultant Cardiologist, nominated by the British Cardiovascular Society – clinical specialist

  • Mrs Christine Owens, Head of Tobacco Control of and nominated by the Roy Castle Lung Cancer Foundation – patient expert

  • Mr David Geldard, President, Heart Care Partnership (UK), nominated by the British Cardiovascular Society – patient expert